Search Articles

View query in Help articles search

Search Results (1 to 10 of 3263 Results)

Download search results: CSV END BibTex RIS


Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial

Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial

It was administered in doses ranging between 0.01 and 0.1 g/kg, 3 times daily either orally or intravenously (equivalent to 2.4-24 g/d for an 80 kg patient). Among patients with schizophrenia and catatonia, approximately 30 participants, the study showed a reduction of catatonic symptoms ranging from 60% to 70%. Specifically, there were improvements in anxiety, agitation, and restlessness.

Lilian Bot, Josine G van Mill, Laetitia J C A Smarius, Adriaan W Hoogendoorn, Bram W C Storosum, Christiaan H Vinkers, Gabriel E Jacobs, Gert Jan Lammers, Hanna M Heller, Jantine C A Colen-de Koning, Joris J B van der Vlugt, Marloes S Oudijn, Martijn S van Noorden, Pierre M Bet, Rolf Fronczek, Heleen S van der Heijden, Sjors M M Lange, Ysbrand D van der Werf, Eric R van Exel

JMIR Res Protoc 2025;14:e68356

Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infection Testing and Pre-Exposure Prophylaxis Initiation Among Rural Men Who Have Sex With Men in the Southern United States: Protocol for a Randomized Controlled Trial

Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infection Testing and Pre-Exposure Prophylaxis Initiation Among Rural Men Who Have Sex With Men in the Southern United States: Protocol for a Randomized Controlled Trial

Example screenshots of the Study Management and Retention Tool (SMa RT) web application, including the different Combine intervention content sections: (A) log in screen, (B) study timeline, (C) intervention content home screen, (D), health resources section, (E) frequently asked questions about pre-exposure prophylaxis. This section includes the major time points of the study (baseline, month 6, month 12, month 18, and month 24). It allows participants to see upcoming and previously completed surveys.

Jeb Jones, Georgia Manley, Tiffany R Glynn, Kristin M Wall, Stefan D Baral, E Danny Harris, David Benkeser, Patrick S Sullivan

JMIR Res Protoc 2025;14:e69540

Intervention for Justice-Involved Homeless Veterans With Co-Occurring Substance Use and Mental Health Disorders: Protocol for a Randomized Controlled Hybrid Effectiveness-Implementation Trial

Intervention for Justice-Involved Homeless Veterans With Co-Occurring Substance Use and Mental Health Disorders: Protocol for a Randomized Controlled Hybrid Effectiveness-Implementation Trial

To address the unique needs of veterans and civilians with COD and criminal legal involvement, an adaptation of MISSION, the criminal justice (MISSION-CJ) version was developed (Pinals, DA, unpublished manual, April 2014 and Smelson, D, unpublished manual, June 2014). MISSION-CJ is guided by the risk-need-responsivity framework of offender rehabilitation, which posits that rehabilitation should target “criminogenic needs” (ie, modifiable factors that are robust predictors of recidivism) [49,50].

Kathryn Bruzios, Paige M Shaffer, Daniel M Blonigen, Michael A Cucciare, Michael Andre, Thomas Byrne, Jennifer Smith, David Smelson

JMIR Res Protoc 2025;14:e70750

Natural Language Processing for Identification of Hospitalized People Who Use Drugs: Cohort Study

Natural Language Processing for Identification of Hospitalized People Who Use Drugs: Cohort Study

The presence of any of the following criteria (ie, abbreviated with the letters B, D, M, and N) were used to qualify the hospitalizations for inclusion in the PWUD cohort: B (Biomarkers): In line with a previous study, positive urine toxicology for drugs or medications for SUD (eg, cocaine, amphetamine, methadone, suboxone, fentanyl, opiate, oxycodone), positive HCV antibody with positive or quantifiable HCV viral load [29] D (Diagnostic codes): Presence of ICD-9 and or ICD-10 code for overdose, substance use

Taisuke Sato, Emily D Grussing, Ruchi Patel, Jessica Ridgway, Joji Suzuki, Benjamin Sweigart, Robert Miller, Alysse G Wurcel

JMIR AI 2025;4:e63147